Full Product Name
CBP Antibody: Dylight 350
Product Synonym Names
Rabbit Anti-Human CBP Polyclonal; RSTS Antibody; CBP_HUMAN Antibody; Cyclic AMP responsive enhancer binding protein Antibody; Crebbp Antibody; CREB-binding protein Antibody; Rubinstein Taybi syndrome Antibody; KAT3A Antibody; EC:2.3.1.48 Antibody; CREBBP Antibody; CBP Antibody; RTS Antibody; CREB binding protein Antibody
Product Gene Name
anti-CBP antibody
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q92793
Specificity
Detects 265 kDa.
Purity/Purification
Peptide Affinity Purified
Form/Format
PBS pH 7.4, 50% Glycerol, 0.09% Sodium Azide
Concentration
1 mg/ml (lot specific)
Immunogen
Synthetic peptide from the mid-protein of Human CBP (aa. 2100-2200)
Cellular Localization
Cytoplasm; Nucleus
Certificate of Analysis
A 1:1000 dilution was sufficient for detection of CBP in 10 ug of human HeLa cell lysates by ECL immunoblot analysis using goat anti-rabbit IgG:HRP as the secondary antibody.
Product Notes
Conjugated primary antibodies can be good options or alternatives to secondary antibody's for detecting a target protein. The lab manufactures a conjugated antibody from a primary parent antibody by attaching (conjugating) an available tag such as a fluorophore or protein, allowing detection of the target protein without using a secondary antibody. Conjugated primary antibodies may potentially be used to replace primary/secondary antibody pairs in various applications, such as Enzyme-Linked Immunosorbent Assay (ELISA), Flow Cytometry, Fluorescence-activated cell sorting, Förster Resonance Energy Transfer (FRET). Immunocytochemistry, Immunofluorescence, Immunohistochemistry, or Western Blot. The suitability of applications for conjugates are user determined and we cannot guarantee that any antibody-conjugate combination has been tested for use in a particular application.
Please note: Conjugate tags may potentially bind in the antibody paratope, which can limit binding of the antibody to the antigen. Binding in the antibody paratope may affect the ability of the antibody to bind to the corresponding antigen (protein target) in various species and applications. There is no way to confirm or guarantee the location of the antibody tag as we cannot control the binding of the conjugate to the antibody. Researchers are responsible for evaluating antibody conjugates for the suitability of their applications.
Preparation and Storage
Store at-20 degree C.
Other Notes
Small volumes of anti-CBP antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Product Categories/Family for anti-CBP antibody
Cell Signaling; Epigenetics and Nuclear Signaling; Chromatin Modifying Enzymes; Transcription; Stem Cells; Signaling Pathways; Wnt/Beta Catenin Pathway; Cancer; Cancer Metabolism; Cancer Lipid and Lipoprotein Metabolism; Cancer; Cancer Metabolism; Respons
Applications Tested/Suitable for anti-CBP antibody
Western Blot (WB), Immunohistochemistry (IHC)
Application Notes for anti-CBP antibody
WB: 1:1000
IHC: 1:50
Immunohistochemistry (IHC) of anti-CBP antibody
Immunohistochemistry analysis using Rabbit Anti-CBP Polyclonal Antibody. Tissue: Breast Cancer. Species: Human. Fixation: Formalin Fixed Paraffin-Embedded. Primary Antibody: Rabbit Anti-CBP Polyclonal Antibody. Lane 1: Molecular Weight Ladder (MW). Lane 2: HeLa. Load: 10 ug. Block: 5% Skim Milk in 1X TBST. Primary Antibody: Rabbit Anti-CBP Polyclonal Antibody at 1:1000 for 2 hours at RT. Secondary Antibody: Goat Anti-Rabbit IgG: HRP at 1:4000 for 1 hour at RT. Color Development: ECL solution for 5 min at RT. Predicted/Observed Size: ~265.3 kDa.
NCBI/Uniprot data below describe general gene information for CBP. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001073315.1
[Other Products]
NCBI GenBank Nucleotide #
NP_001073315.1
[Other Products]
UniProt Primary Accession #
Q92793
[Other Products]
UniProt Related Accession #
Q92793[Other Products]
NCBI Official Full Name
CREB-binding protein isoform b
NCBI Official Synonym Full Names
CREB binding protein
NCBI Official Symbol
CREBBP [Similar Products]
NCBI Official Synonym Symbols
CBP; RSTS; KAT3A; MKHK1; RSTS1
[Similar Products]
NCBI Protein Information
CREB-binding protein
UniProt Protein Name
CREB-binding protein
Protein Family
CBP3-like protein
UniProt Gene Name
CREBBP [Similar Products]
UniProt Synonym Gene Names
CBP [Similar Products]
UniProt Entry Name
CBP_HUMAN
NCBI Summary for CBP
This gene is ubiquitously expressed and is involved in the transcriptional coactivation of many different transcription factors. First isolated as a nuclear protein that binds to cAMP-response element binding protein (CREB), this gene is now known to play critical roles in embryonic development, growth control, and homeostasis by coupling chromatin remodeling to transcription factor recognition. The protein encoded by this gene has intrinsic histone acetyltransferase activity and also acts as a scaffold to stabilize additional protein interactions with the transcription complex. This protein acetylates both histone and non-histone proteins. This protein shares regions of very high sequence similarity with protein p300 in its bromodomain, cysteine-histidine-rich regions, and histone acetyltransferase domain. Mutations in this gene cause Rubinstein-Taybi syndrome (RTS). Chromosomal translocations involving this gene have been associated with acute myeloid leukemia. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Feb 2009]
UniProt Comments for CBP
CBP: a protein acetyltransferase that can transcriptionally activate histones. Acetylates the NCOA3 coactivator. Binds specifically to phosphorylated CREB1 and enhances its transcriptional activity toward cAMP-responsive genes. Methylation of the KIX domain by CARM1 blocks association with CREB, blocking CREB signaling, and activating the apoptotic response. Found in a complex containing NCOA2, NCOA3, IKKA, IKKB, and IKBKG. Probably part of a complex with HIF1A and EP300. Interacts with the C-terminal region of CITED4. The TAZ-type 1 domain interacts with HIF1A. Interacts with MAF, SRCAP, CARM1, ELF3, MLLT7/FOXO4, N4BP2, NCOA1, NCOA3, NCOA6, PCAF, PELP1, PML, SMAD1, SMAD2, SMAD3, SPIB and TRERF1. Interacts with HTLV-1 Tax, p30II, and HIV-1 Tat. Interacts with KLF1; the interaction results in acetylation of KLF1 and enhancement of its transcriptional activity. Interacts with ZCCHC12. Interacts with DAXX; the interaction is dependent on CBP sumoylation and results in suppression of the transcriptional activiy via recruitment of HDAC2 to DAAX. Interacts with MTDH. Interacts with NFATC4. Interacts with MAFG; the interaction acetylates MAFG in the basic region and stimulates NFE2 transcriptional activity through increasing its DNA-binding activity. Interacts with IRF2; the interaction acetylates IRF2 and regulates its activity on the H4 promoter. Interacts via its N-terminus with the C-terminus of SS18L1. Interacts with MECOM. Chromosomal aberrations involving CBP may be a cause of acute myeloid leukemias. Known translocation partners include MYST3, MLL, and MYST4. MYST3-CBP fusion proteins may induce leukemia by inhibiting RUNX1-mediated transcription. Defects in CBP are a cause of Rubinstein-Taybi syndrome type 1 (RSTS1), an autosomal dominant disorder characterized by craniofacial abnormalities, broad thumbs, broad big toes, mental retardation and a propensity for development of malignancies.
Protein type: Motility/polarity/chemotaxis; DNA-binding; EC 2.3.1.48; Nuclear receptor co-regulator; Transcription, coactivator/corepressor; Acetyltransferase
Chromosomal Location of Human Ortholog: 16p13.3
Cellular Component: nucleoplasm; nuclear body; transcription factor complex; nuclear chromatin; cytoplasm; outer kinetochore of condensed chromosome; nucleus; histone acetyltransferase complex
Molecular Function: protein binding; signal transducer activity; MRF binding; histone acetyltransferase activity; zinc ion binding; p53 binding; acetyltransferase activity; transcription coactivator activity; chromatin binding; transcription factor activity; transcription factor binding
Biological Process: transcription initiation from RNA polymerase II promoter; establishment and/or maintenance of chromatin architecture; Notch signaling pathway; viral reproduction; positive regulation of transcription, DNA-dependent; rhythmic process; germ-line stem cell maintenance; negative regulation of transcription from RNA polymerase II promoter; cellular lipid metabolic process; signal transduction; regulation of transcription, DNA-dependent; homeostatic process; response to hypoxia; positive regulation of interferon type I production; innate immune response; gene expression; protein complex assembly; positive regulation of transcription from RNA polymerase II promoter; embryonic digit morphogenesis; histone acetylation; N-terminal peptidyl-lysine acetylation; regulation of smoothened signaling pathway
Disease: Rubinstein-taybi Syndrome 1
Research Articles on CBP
1. CREBBP gene mutations are frequently detected in in situ follicular neoplasia.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
